Optimization and validation of the production of new generation probiotics for obesity. Line Valorization, transfer and exploitation by companies of R&D results. AVI, Valencian Agency of Innovation. Ref: INNVA1/2020/25. 2020- 2021. Principal Investigator: Prof. Yolanda Sanz..
This project aims to evaluate the safety, production feasibility and stability of a new intestinal bacteria to be used as probiotic or live bio-therapeutic product (LBP) for obesity and associated metabolic disorders, like type-2 diabetes.
Objectives
- Evaluate the safety of the long-term oral administration of the bacterium in vivo.
- Optimization of bacterial production and up-scaling in bioreactors.
- Improvement of the stability through microencapsulation.
Strategy
- Well-establish 90-day toxicity study models and readouts (immune, microbiome, enzymatic etc.) to evaluate the safety of our bacterium
- Bioreactors of different sizes (from 1 ml to 0.5 L and up-to 5 L) to optimize growth and scalability
- Microencapsulation techniques in collaboration with AINIA to increase stability
Impact
- Know-how in up-scaling cultures of anaerobic intestinal bacteria
- Progress towards the commercialization of the bacterium patented for obesity and metabolic complications